Immunome Inc.
IMNM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001472012
In the last 90 days, Immunome Inc. insiders filed 0 open-market purchases and 7 sales; 202 institutions reported holding it in 13F filings for Q2 2026, worth $2.50B in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Immunome Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 57 | 103 | +46 |
| Shares | 21.5M | 36.6M | +15.1M (+70.4%) |
| Value | $229.9M | $903.6M | +$673.7M (+293.0%) |
New holders (57)
Institutions that held Immunome Inc. at the end of Q1 2024 but not at the end of Q4 2023.
Sold out (11)
Institutions that held Immunome Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| Prentice Capital Management, LP | 112,131 | $1.20M |
| Mayo Clinic | 108,480 | $1.16M |
| 683 Capital Management, LLC | 27,149 | $290.5K |
| HighTower Advisors, LLC | 16,818 | $180.0K |
| Jump Financial, LLC | 16,100 | $172.3K |
| Bank of New York Mellon Corp | 15,844 | $169.5K |
| Dimensional Fund Advisors LP | 14,054 | $150.4K |
| Mirabella Financial Services LLP | 12,200 | $130.5K |
| Lazard Asset Management LLC | 7,700 | $82.0K |
| Citadel Advisors LLC | 2,630 | $28.1K |
| Newbridge Financial Services Group, Inc. | 225 | $2.41K |